- Home
- ALAR vs OTLK Comparison
ALAR vs OTLK Comparison
Compare ALAR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- OTLK
- Stock Information
- Founded
- ALAR 2013
- OTLK 2010
- Country
- ALAR Israel
- OTLK United States
- Employees
- ALAR N/A
- OTLK N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALAR Technology
- OTLK Health Care
- Exchange
- ALAR Nasdaq
- OTLK Nasdaq
- Market Cap
- ALAR 45.3M
- OTLK 48.3M
- IPO Year
- ALAR 2018
- OTLK 2016
- Fundamental
- Price
- ALAR $11.05
- OTLK $1.71
- Analyst Decision
- ALAR Strong Buy
- OTLK Strong Buy
- Analyst Count
- ALAR 1
- OTLK 5
- Target Price
- ALAR $15.00
- OTLK $9.60
- AVG Volume (30 Days)
- ALAR 232.8K
- OTLK 819.5K
- Earning Date
- ALAR 05-29-2025
- OTLK 08-13-2025
- Dividend Yield
- ALAR N/A
- OTLK N/A
- EPS Growth
- ALAR N/A
- OTLK N/A
- EPS
- ALAR 0.07
- OTLK 0.83
- Revenue
- ALAR $30,581,000.00
- OTLK N/A
- Revenue This Year
- ALAR N/A
- OTLK N/A
- Revenue Next Year
- ALAR $12.28
- OTLK $379.84
- P/E Ratio
- ALAR $16.75
- OTLK $2.07
- Revenue Growth
- ALAR 4.67
- OTLK N/A
- 52 Week Low
- ALAR $5.45
- OTLK $0.87
- 52 Week High
- ALAR $46.69
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- ALAR 65.81
- OTLK 46.49
- Support Level
- ALAR $10.43
- OTLK $1.65
- Resistance Level
- ALAR $12.25
- OTLK $1.97
- Average True Range (ATR)
- ALAR 0.83
- OTLK 0.12
- MACD
- ALAR 0.21
- OTLK -0.03
- Stochastic Oscillator
- ALAR 73.26
- OTLK 10.94
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.